PB 1046

Drug Profile

PB 1046

Alternative Names: PB-1046; Vasomera

Latest Information Update: 01 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator PhaseBio Pharmaceuticals
  • Class Antihypertensives; Peptide hormones; Recombinant fusion proteins
  • Mechanism of Action Vasoactive intestinal peptide type II receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cardiomyopathies; Pulmonary arterial hypertension
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Cardiomyopathies; Heart failure
  • Phase I Pulmonary arterial hypertension
  • Preclinical Cystic fibrosis
  • No development reported Essential hypertension

Most Recent Events

  • 27 Feb 2018 PhaseBio Pharmaceuticals receives SBIR grant from National Institutes of Health for PB 1046 development in Pulmonary arterial hypertension
  • 27 Feb 2018 PhaseBio Pharmaceuticals plans a phase II trial for pulmonary arterial hypertension in mid-2018
  • 20 Oct 2017 Phase-I clinical trials in Pulmonary arterial hypertension in USA (SC) (NCT03315507)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top